$AQST

AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky

Levi & Korsinsky is alerting investors about a securities fraud lawsuit against Aquestive Therapeutics, Inc. (AQST). The lawsuit alleges that investors who purchased AQST securities between June 16, 2025, and January 8, 2026, suffered significant losses after an analyst slashed the price target due to identified deficiencies in the FDA's review of Anaphylm, which contradicted management's prior assurances. The firm is encouraging affected investors to seek to lead the class action by the May 4, 2026 deadline.

Original reporting
Published Mar 18, 2026, 12:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 18, 2026, 1:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$AQST
Bearish
high confidence
Mentioned
$AQST
alphai data visualization · based on PR Newswire
Decision brief

The 30-second read

$AQSTBearishHigh
01

Why it matters

The lawsuit and analyst downgrade have heightened bearish sentiment, likely leading to short-term price declines.

02

Market read

Legal and regulatory issues significantly impact AQST's stock, with potential spillover effects on biotech sector sentiment.

03

What to watch

Possible positive developments in FDA review or company disclosures could mitigate downside.

Timing: Immediate, as legal proceedings and analyst reports are current.

Background

Recent legal filings allege securities fraud related to FDA review processes, causing investor concern.

Company-level read

Ticker impact

$AQSTBearishHigh confidence
Context

High relevance due to recent securities fraud lawsuit and significant bearish sentiment.

Expected impact

Potential short-term decline of 10-15% as investors react to legal and regulatory concerns.

Evidence & confidence

Legal actions and analyst downgrades typically lead to negative price movements, especially when accompanied by bearish sentiment and significant losses among investors.

Market effects

Potential negative sentiment in the life sciences sector, especially among biotech firms with FDA interactions.

Limited regional impact; primarily affects US-based biotech stocks.

Moderate, as US biotech sector is significant but not globally dominant.

Counterpoint

Legal actions may be fact-specific and not indicative of broader company or sector health; potential for recovery if legal issues are resolved favorably.

Key entities

  • Levi & Korsinsky

    Legal firm alerting investors about the lawsuit.

  • AQST

    Aquestive Therapeutics, Inc., involved in the legal case.

  • FDA

    U.S. Food and Drug Administration, involved in the review process.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.